Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:941085.
doi: 10.1155/2014/941085. Epub 2014 Aug 27.

Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials

Zongguo Yang  1 , Liping Zhuang  2 , Yunfei Lu  1 , Qingnian Xu  1 , Xiaorong Chen  1
Affiliations
Review

Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials

Zongguo Yang et al. Biomed Res Int. 2014.

Abstract

Objective: This study aimed to evaluate the efficacy and safety of silymarin on chronic hepatitis C virus- (HCV-) infected patients.

Methods: Randomized controlled trials (RCTs) of silymarin in chronic HCV-infected patients up to April 1, 2014 were systematically identified in PubMed, Ovid, Web of Science, and Cochrane Library databases.

Results: A total of 222 and 167 patients in five RCTs were randomly treated with silymarin (or intravenous silibinin) and placebo, respectively. Serum HCV RNA relatively decreased in patients treated with silymarin compared with those administered with placebo, but no significance was found (P = 0.09). Meta-analysis of patients orally treated with silymarin indicated that the changes of HCV RNA are similar in the two groups (P = 0.19). The effect on alanine aminotransferase (ALT) of oral silymarin is not different from that of placebo (P = 0.45). Improvements in quality-of-life (Short Form-36) in both silymarin and placebo recipients were impressive but relatively identical (P = 0.09).

Conclusion: Silymarin is well tolerated in chronic HCV-infected patients. However, no evidence of salutary effects of oral silymarin has yet been reported based on intermediate endpoints (ALT and HCV RNA) in this population. Moreover, intravenous administration of silymarin should be further studied.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk of bias assessment. (a) Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. (b) Risk of bias summary: review authors' judgments about each risk of bias item for each included study.
Figure 2
Figure 2
Changes of HCVRNA level.
Figure 3
Figure 3
Changes of ALT level.
Figure 4
Figure 4
Quality of life by SF-36.
See this image and copyright information in PMC

References

    1. Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. The American Journal of Gastroenterology. 2002;97(9):2391–2397. - PubMed
    1. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47(2):605–612. - PubMed
    1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374. - PMC - PubMed
    1. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World Journal of Gastroenterology. 2011;17(18):2288–2301. - PMC - PubMed
    1. Althagafy HS, Graf TN, Sy-Cordero AA, et al. Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. Bioorganic and Medicinal Chemistry. 2013;21(13):3919–3926. - PMC - PubMed

MeSH terms

LinkOut - more resources